Clinical Trial Agreement Site Consent and Change of Control in CRO M&A: Investigator Approvals, IRB Coordination, and Budget Amendments

CTA Structure Overview: Sponsor, CRO, Site, and Investigator Roles

A clinical trial agreement in the CRO context is typically a tripartite or multi-tier arrangement. At the top of the structure sits the sponsor, the pharmaceutical, biotechnology, or medical device company that holds the IND or IDE and bears ultimate regulatory responsibility for the trial under 21 CFR 312.50. The sponsor delegates day-to-day operational oversight to the CRO through a master services agreement or a study-specific task order, with the CRO assuming the obligations listed in that delegation. At the site level, the CTA is the operative document governing the relationship between the CRO (acting on behalf of or in the name of the sponsor) and the clinical site, which is typically a hospital, academic medical center, physician group, or independent research facility.

The principal investigator is a distinct party from the site institution, even though both typically sign the CTA. The investigator holds personal regulatory obligations under 21 CFR 312.60 and executes Form FDA 1572, the Statement of Investigator, which creates a direct commitment to FDA to conduct the trial in accordance with the protocol and to comply with applicable regulations. This personal commitment is not an organizational obligation of the site alone; it attaches to the named investigator individually. A change in the CRO's corporate identity does not automatically release or modify the investigator's Form 1572 obligations, but it does raise the question of whether the named CRO on the investigator's 1572 submission to FDA accurately reflects the new contracting entity.

CTA terms address the rights and obligations of the site and investigator in substantial detail. The agreement typically covers the scope of protocol-defined activities the site will perform, the per-subject and milestone compensation structure, the IP and publication rights that the investigator retains, the indemnification the CRO provides for harm to subjects, the data ownership and use rights the sponsor or CRO holds, and the termination provisions that govern how the relationship ends if the trial is stopped or the sponsor's program is discontinued. Each of these terms becomes a variable in the M&A analysis when the CRO changes hands.

Sub-investigator designations and site staff dependencies are a secondary structural consideration. Many CTAs identify sub-investigators by name, creating an obligation to update FDA records if those individuals change. Some agreements also tie the site's compensation schedule to the continued involvement of the named principal investigator, creating a right of renegotiation if the PI leaves during the trial. In a CRO acquisition, buyers must assess whether any named investigators or sub-investigators are likely to reassign to a different institution or withdraw from the trial as a consequence of the change of control, since these events trigger additional regulatory notification requirements under 21 CFR 312.62 and may delay subject enrollment at affected sites.

Master CTA vs. Site-Specific CTA Amendments at Close

CROs that operate large trial networks typically manage their site relationships through one of two contractual structures: a master CTA with study-specific work orders, or individual site-specific CTAs executed on a trial-by-trial basis. The structural choice has direct implications for how the M&A transaction team must approach consent and amendment workstreams.

Under a master CTA framework, a single master agreement establishes the general terms governing all studies at a given site, and individual work orders or study-specific addenda incorporate study-specific protocols, budgets, and schedules. The change of control provision in the master CTA governs every study covered by that master, meaning that a single consent or notice satisfies the contractual requirement across all studies at that site simultaneously. This architecture reduces the transactional burden significantly for large site networks: instead of executing hundreds of site-specific amendments, the transaction team can focus on obtaining a single consent or providing a single notice under each master CTA. However, buyers must verify that the work orders themselves do not contain independent change of control provisions that override the master, a structuring error that some CROs have introduced inadvertently when adapting standard work order templates.

Site-specific CTAs require individual treatment. Each agreement must be reviewed for its own assignment and change of control language, and the consent or notice obligation must be satisfied under the specific terms of that agreement. Where the site-specific CTA lacks any change of control provision, state contract law governs assignment, and in most jurisdictions a contract for personal services or one that places substantial reliance on the specific identity of the contracting party is not freely assignable without consent. CRO service agreements, which depend on the site's trust in the CRO's operational capacity and compliance culture, are routinely treated as involving personal service elements sufficient to trigger the anti-assignment principle.

Amendment campaigns in a CRO acquisition typically begin four to six weeks before the anticipated closing date. The campaign requires the preparation of a consent or amendment form for each site, identification of the correct execution authority at each institution (which may be a sponsored programs office, general counsel, or department chair rather than the investigator), tracking of signature receipt, and follow-up for non-responsive sites. CRO acquisitions involving 50 or more active sites should treat the consent campaign as a dedicated project with a named coordinator and a weekly reporting mechanism to deal counsel. Sites that have not consented by closing are a residual risk that must be documented and managed through a post-closing remediation plan.

Change of Control Provisions: Consent vs. Notice Requirements

The distinction between a consent requirement and a notice requirement in a CTA's change of control provision is the most consequential threshold in the CRO M&A diligence analysis. A consent requirement means the site must affirmatively agree to the change before it becomes effective, giving the site a practical veto over whether it continues the trial with the acquirer. A notice requirement means the CRO or the acquirer must inform the site of the change within a specified period, but the site has no contractual right to block the succession.

Consent provisions introduce deal risk in two ways. First, a site that withholds consent can effectively terminate its participation in the trial, which reduces the acquired CRO's active site count and potentially impairs the target's representations about pipeline continuity. Second, a site that conditions its consent on budget renegotiation or other concessions can extract value from the acquirer in the days immediately following signing, when the buyer has limited leverage and the site is aware of it. Diligence should quantify the consent exposure by reviewing every active CTA and categorizing each site as consent-required, notice-only, or silent. The consent-required category should be analyzed further to identify which sites are high-volume contributors to active trials, since their refusal or renegotiation would be most damaging.

Notice provisions carry lower transactional risk but are not risk-free. Many CTAs specify the notice period (30, 60, or 90 days is common) and the form of notice (written, to a specified address or contact). A notice that is defective in form or timing can be treated by the site as a failure to satisfy the contractual condition, potentially elevating the notice failure to a breach. Where notice must be provided before the closing date (as opposed to after), the CRO must disclose the transaction to all sites before the deal is public, which creates confidentiality complications that should be addressed in the non-disclosure agreement and the purchase agreement's pre-closing covenants.

Agreements that are silent on change of control must be analyzed under the applicable state's contract law. In stock acquisitions, silence on change of control is less problematic because the legal entity contracting with the site does not change. In asset acquisitions, silence creates genuine uncertainty. Some jurisdictions hold that an asset purchase constitutes an assignment requiring consent under general principles; others permit the assignment where the acquirer assumes all obligations and the assignment is not materially adverse to the counterparty. Buyers in asset acquisitions should not rely on silence to mean consent is not required without a specific legal analysis of the governing state law for each affected agreement.

Investigator Consent Rights and Form FDA 1572 Coordination

Form FDA 1572 is the Statement of Investigator required under 21 CFR 312.53(c) for each principal investigator participating in a clinical trial under an IND. The form requires the investigator to identify the sponsor of the study by name, commit to compliance with the protocol and applicable regulations, identify the IRB that will review the study, and disclose any financial interests that could affect the conduct or reporting of the trial. When the CRO changes hands, the identity of the sponsor or the contracting CRO as listed on the investigator's 1572 may become inaccurate.

Whether a change of control in the CRO requires an amended 1572 depends on whether the form identifies the CRO or the ultimate sponsor by name in the sponsor field. In trials where the pharmaceutical sponsor holds the IND and the CRO acts as a delegated operator, the sponsor field on the 1572 identifies the pharmaceutical company, not the CRO, meaning that a change in CRO identity does not require an amended 1572 for those trials. In trials where the CRO itself holds the IND and operates as the regulatory sponsor, a change in CRO identity does require the investigator to file an amended 1572 with the new sponsor's name, because the existing form is factually inaccurate and may mislead FDA about the regulatory accountability chain.

Some CTAs include provisions specifically addressing investigator consent to changes in the sponsoring organization. These provisions may give the investigator a right to withhold consent to any assignment of the CTA or to require renegotiation of specific terms before consenting. Investigator consent rights at academic medical centers are frequently more robust than at independent research sites, because institutional conflict of interest policies require formal review and disclosure whenever a new sponsor relationship is created. The investigator's institutional conflict of interest officer may have separate approval authority over the continuation of a trial with a new sponsor, creating an additional consent layer that the CTA does not explicitly address.

Financial disclosure forms under 21 CFR Part 54, specifically Forms FDA 3454 and 3455, must be updated whenever there is a change in the financial relationship between an investigator and the sponsor or applicant. If the CRO acquisition results in the investigator receiving equity, payments, or other financial interests in the acquiring entity, an updated financial disclosure form must be filed. Buyers who issue equity or retention payments to investigators at acquired sites as part of the deal integration should structure those arrangements carefully to avoid triggering financial disclosure obligations that could affect the regulatory status of the clinical data associated with those investigators.

Central IRB vs. Local IRB Reliance and Change Notifications

The 2018 amendments to the Common Rule at 45 CFR Part 46 require that domestic institutions engaged in cooperative research subject to the Common Rule use a single IRB of record for each protocol unless an exception applies. This single IRB requirement has accelerated the use of central IRBs, particularly commercial IRBs, for multi-site CRO-sponsored trials. The IRB reliance architecture has direct implications for how a CRO acquisition affects the regulatory status of ongoing trials.

Under a central IRB model, the reviewing IRB holds a reliance agreement with each participating site, and the CRO or sponsor holds a separate services agreement with the central IRB governing the review process and fee arrangements. In a CRO acquisition, the services agreement between the CRO and the central IRB is an assumed contract that must be addressed in the purchase agreement. The central IRB's own terms of service may contain a change of control provision requiring its consent or notification before the services agreement can be assigned. A central IRB that receives no notification of the acquisition may continue issuing approvals under the original CRO's name, creating a documentation discrepancy between the IRB's records and the actual sponsor of record.

Local IRBs at sites that retain their own independent review function, rather than relying on a central IRB, must each be notified of the CRO change. The Common Rule requires prompt reporting of changes that may affect the rights and welfare of subjects or the conduct of the research. A change in the contracting CRO is typically treated as a reportable change requiring notification, even if the protocol itself is unchanged. Some local IRBs require a formal amendment submission and a scheduled review meeting before they will confirm that the trial may continue with the new sponsor of record. Buyers should map all active trials to their reviewing IRB, identify which are under a local review model, and budget for the notification and confirmation workload.

IRB notification requirements interact with the CTA consent campaign in a sequencing problem that deal teams frequently underestimate. Sites cannot agree to continue the trial with the new CRO before they know the new CRO's identity and have assessed the change under their institutional review process. IRBs cannot issue a notification acknowledgment until they receive a complete notification package identifying the new sponsor and describing the nature of the change. These processes must run in parallel and cannot be completed instantaneously, which means the transaction timeline must reserve adequate space between signing and closing for both workstreams to advance. Transactions that attempt to close within two weeks of signing a CRO acquisition routinely encounter IRB notification problems that delay the effective transfer of operational control.

Budget Amendments and Investigator Payment Mechanics

Investigator payment structures in clinical trial agreements are more complex than standard vendor payment arrangements. A typical CTA budget covers startup activities (site initiation visits, IRB submission fees, staff training), per-subject costs (screening, enrollment, per-visit procedures, and laboratory fees), protocol amendment fees, and close-out activities. Payments are generally milestone-triggered rather than time-based, and they depend on the CRO's receipt and acceptance of visit documentation from the site. The backlog of pending visit documentation and the associated unpaid obligations are among the most important financial disclosures a seller must make in a CRO transaction.

Budget amendments arise when the protocol changes in ways that affect site workload. A protocol amendment that adds a new assessment visit, requires an additional blood draw, or changes the subject eligibility criteria may entitle the site to additional per-visit compensation or a protocol amendment fee. Under the standard CTA framework, budget amendments require negotiation between the CRO and the site, documentation of the agreed change in the form of a CTA amendment, and in some cases IRB notification if the amendment alters the subject's experience or risk profile. In a CRO acquisition, pending budget amendment negotiations that have not been finalized represent contingent obligations that the buyer is inheriting without certainty about their ultimate cost.

The mechanics of investigator payment in many CROs involve a clinical payment management system, such as Medidata Rave, Veeva Payments, or a proprietary system, that tracks visit completion, applies per-visit rates from the executed CTA budget, and generates payment to sites on a defined cycle. In an acquisition, the buyer must determine whether these systems will be transferred, replaced, or maintained through a transition services arrangement, and whether the sites will experience any disruption in payment processing during the transition. Payment disruptions are a significant source of post-closing site dissatisfaction and, if sustained, can constitute a breach of the assumed CTA's payment obligations.

Fair market value requirements add a regulatory dimension to CTA budget amendments that is not present in most commercial contracts. The HHS Office of Inspector General and the Department of Justice have established that payments to investigators under clinical trial agreements must reflect fair market value for the services rendered, without taking into account the investigator's referral patterns or the volume of business the site generates for the CRO. Where the CRO has historically offered above-market rates to high-volume sites as an inducement to participate in future trials, those rates may implicate the Anti-Kickback Statute in federally funded research contexts. Buyers should request a fair market value analysis for the top quartile of investigator payment rates in the acquired CRO's portfolio and assess whether any arrangements warrant restructuring before closing.

Publication Rights and Intellectual Property Transition

Publication rights in clinical trial agreements reflect a carefully negotiated balance between the investigator's academic interest in communicating research results and the sponsor's interest in controlling the timing and content of public disclosures. The typical formulation gives the investigator the right to publish results after the sponsor has had an opportunity to review the manuscript for confidential information and to file any necessary patent applications. The review period varies from 30 to 90 days in most CTAs, and the sponsor generally cannot block publication outright, only delay it to protect legitimate IP interests.

In a CRO acquisition, publication rights that are held by the original contracting CRO on behalf of the pharmaceutical sponsor transfer to the acquirer. The acquirer steps into the CRO's contractual position as the reviewer of manuscripts, the party responsible for notifying sites of patentable inventions, and the gatekeeper for clinical data confidentiality. If the acquirer is itself a pharmaceutical or biotechnology company, rather than a pure-play CRO, this transition may create a conflict of interest if the acquirer competes in the same therapeutic area as the sponsor's program. Such conflicts should be disclosed to the sponsor and addressed through a specific firewall or exclusion protocol in the transition plan.

Foreground intellectual property that vests in the CRO under the CTA's IP assignment clause is an asset of the acquisition. CROs routinely develop operational know-how, data collection instruments, and analytical methodologies during trial execution, and some CTAs assign ownership of these developments to the CRO rather than the sponsor. Buyers should identify all CTA provisions that assign IP ownership to the CRO and confirm that such assignments are valid and unencumbered. Where the sponsor holds a license back to IP that vested in the CRO, that license must be maintained post-closing, and the acquirer must honor the license terms even if its own use of the underlying IP is more expansive than the CRO's was.

Regulatory data rights are distinct from publication rights and deserve separate attention. FDA's regulations at 21 CFR 314.50(d)(5)(ii) and 312.23 require that the IND or NDA sponsor hold rights to use all clinical data submitted in support of the application. Where the CRO holds the IND and the CTA does not contain an explicit data use agreement granting the sponsor rights to use the site's clinical data in FDA submissions, there may be a gap in the regulatory data rights chain that impairs the value of the acquired pipeline. This is particularly relevant where the CRO has conducted trials under a proprietary research platform or biomarker protocol and the data generated at sites is partially owned by the investigator or the institution under the site's own IP policy.

Indemnification Clauses: Sponsor, CRO, and Site Allocation of Risk

Indemnification in clinical trial agreements operates along a defined risk allocation structure that reflects each party's control over the sources of potential harm. The pharmaceutical sponsor indemnifies the CRO and the site for claims arising from the sponsor's decisions, including the design of the protocol, the content of the investigational product's label or consent form, and any regulatory action taken against the program. The CRO indemnifies the site for operational failures, including monitoring lapses, data management errors, and failures in the CRO's oversight of site activities. The site indemnifies the CRO and sponsor for harm arising from the site's own negligence, including protocol deviations caused by site staff and informed consent failures.

In a CRO acquisition, the buyer assumes the CRO's indemnification obligations to all active and recently completed sites. Active indemnification obligations include ongoing coverage for incidents that occurred during the CRO's performance of the trial and have not yet been fully resolved. More significant is the tail risk: claims arising from site personnel injuries, subject adverse events, or data integrity disputes that occurred before closing but that will not be asserted until after the acquisition closes. The CRO's clinical liability insurance policy must be reviewed to determine whether it covers claims-made or occurrence-basis claims, and whether the policy's tail period extends through the survival period of the CTA's indemnification clause.

The purchase agreement must allocate responsibility for pre-closing indemnification claims with specificity. A common approach is to require the seller to maintain its existing clinical liability insurance for a defined tail period, typically three to five years after closing, with the buyer as an additional insured for claims arising from pre-closing CRO activities. The indemnification in the purchase agreement should mirror this allocation, with the seller retaining responsibility for claims arising from pre-closing CRO conduct and the buyer assuming responsibility for post-closing conduct. The indemnification basket and cap in the purchase agreement should be sized to reflect the known scope of active trials and the historical claims frequency in the CRO's clinical operations.

Subject injury indemnification is the most financially significant category in clinical trial agreement indemnification. Where a trial subject is injured as a result of participation in a CRO-sponsored study, the CTA's indemnification provisions determine whether the CRO or the sponsor bears primary responsibility for medical costs and legal defense. Buyers of CROs must assess whether any active subjects are enrolled in high-risk Phase I or Phase II trials where adverse event rates are elevated, whether any known adverse events from the pre-closing period have not yet been reported to FDA or resolved with the affected subjects, and whether the sponsor's indemnification obligation covers the CRO's legal defense costs in addition to the underlying claim. These factors should be documented in the diligence report and reflected in the purchase agreement's indemnification structure.

Data Use Rights, Research Database Ownership, and HIPAA Authorizations

Clinical trial data generated at research sites is subject to overlapping regulatory frameworks that govern who may use it and for what purposes. FDA regulations require that clinical data submitted in an IND or NDA be held by the sponsor and available for FDA inspection under 21 CFR 312.62. HIPAA's Privacy Rule under 45 CFR Part 164 governs the use and disclosure of protected health information collected from subjects, including health information that is incorporated into clinical trial databases. The Common Rule at 45 CFR Part 46 governs the use of identifiable private information for research purposes. In a CRO acquisition, each of these frameworks affects whether the acquirer may freely use the clinical data that transfers with the business.

HIPAA authorizations for research uses of subject health information are signed by each trial participant at enrollment and specify the purposes for which their information may be used and the entities authorized to use it. In a CRO acquisition, the named entities on existing authorizations may not include the acquirer, raising the question of whether the acquirer's use of subject PHI in ongoing trial operations constitutes a new use requiring a new authorization. FDA's regulatory position is that the IND sponsor's regulatory use of clinical data is a permitted regulatory purpose, not a research purpose requiring re-authorization, but the HIPAA analysis for secondary uses of the data, such as incorporation into a proprietary database, is less clear.

Research database ownership is an asset category that is frequently underspecified in CRO purchase agreements. The CRO's trial databases may include de-identified subject data, biomarker data, protocol-specific quality metrics, site performance benchmarks, and proprietary analytical outputs. Depending on the CTA terms, some of this data may be owned by the sponsor, some by the site (particularly data generated from site-specific assessments), and some by the CRO. Buyers should request a data asset inventory covering every active trial database and confirm the ownership and use rights for each category of data. Where the CRO operates a proprietary data platform that aggregates information across multiple trials, that platform may be one of the most valuable assets in the acquisition, and its ownership must be clearly established before closing.

Business associate agreements under HIPAA govern the CRO's handling of PHI when it acts as a service provider to covered entity sponsors. If the sponsor is a covered entity or a hybrid covered entity, the CRO is a business associate and must operate under a signed BAA. In a CRO acquisition, the BAAs between the CRO and each covered entity sponsor must be reviewed to confirm that they permit the acquirer to assume the CRO's role without the covered entity's prior consent, or to identify which BAAs require amendment. An undisclosed assignment of a BAA without the covered entity's knowledge could constitute a HIPAA violation by the CRO if the BAA contains anti-assignment language, and the buyer could inherit that violation if it is not resolved before closing.

Assignment Prohibitions and Anti-Assignment Workarounds: The Merger Exception

Anti-assignment clauses in clinical trial agreements are among the most frequently litigated provisions in M&A contexts across all industries, and the CRO sector is no exception. The standard formulation prohibits either party from assigning the agreement without the prior written consent of the other party. Some CRO CTAs go further and prohibit assignment even to affiliates, creating a near-total restriction that can apply to every form of transaction structure including stock mergers.

The merger exception, sometimes called the successor exception, is the principal legal argument that buyers in stock acquisitions raise to avoid the consent requirement under a broadly worded anti-assignment clause. Under this doctrine, which has been adopted in most but not all jurisdictions, a statutory merger in which the CRO entity survives as a wholly owned subsidiary of the acquirer does not constitute an assignment because the contracting entity remains unchanged. The CRO entity that signed the CTA is still the same legal entity after the merger, even though its ownership has changed. Courts in Delaware, New York, and most other M&A-significant jurisdictions have upheld this analysis, though the result is not universal and some courts have found that a change in control sufficient to trigger the anti-assignment clause constitutes a prohibited assignment even in a stock transaction.

Asset acquisitions do not benefit from the merger exception. An asset purchase involves an express assignment of the CTA from the selling CRO entity to the acquiring entity, which is precisely what the anti-assignment clause prohibits. Buyers in asset acquisitions must either obtain site consent for each CTA with a restrictive anti-assignment clause, structure the transaction as a stock deal to preserve the merger exception defense, or accept the risk that certain CTAs may be unenforceable post-closing if the counterparties elect to treat the assignment as a breach. The practical risk of site enforcement varies: many sites will not affirmatively challenge a CRO assignment as long as trial operations continue smoothly, but a site that has grievances with the old CRO may use the assignment question as a basis for terminating the agreement and renegotiating terms with the buyer.

Workarounds used in practice include novation agreements, which substitute the buyer as the contracting party with the site's express consent; sub-contracting arrangements, where the selling CRO entity retains nominal contractual responsibility but subcontracts all performance to the buyer during a transition period; and hybrid structures, where the acquisition closes as a stock deal at the CRO entity level while certain assets are hived out to the buyer in a second step after consents have been obtained. Each workaround has legal and regulatory implications that must be analyzed under the specific facts of the transaction and the governing state law of each affected CTA.

Site Subscription Services and SMO Consent Structures

Site management organizations occupy a distinct position in the clinical trial ecosystem. An SMO provides operational infrastructure, staffing, regulatory support, and financial management services to clinical research sites, enabling those sites to participate in trials that they could not staff or fund independently. The SMO typically holds a site management services agreement with each affiliated site and, in many cases, also holds an interest in the site entity itself. In an SMO acquisition, the buyer acquires both the service agreements and, where applicable, ownership interests in the underlying site entities.

Site subscription service agreements, which are the operational backbone of an SMO's business model, typically include change of control provisions that are drafted from the site's perspective rather than the SMO's. Sites that depend on an SMO for regulatory compliance support, IRB access, and trial recruitment infrastructure have a strong interest in controlling who their SMO partner is. A change in the SMO's ownership can affect the site's willingness to continue participating in SMO-sponsored trials and, in some cases, its ability to maintain accreditation or licensing if the SMO's compliance infrastructure is disrupted during the transition.

SMO consent structures frequently include a right of first refusal or a right to renegotiate terms if the SMO changes hands. Some site service agreements give the site an outright termination right triggered by the SMO's change of control, exercisable within 30 to 60 days of notice. Where sites hold termination rights, the buyer must assess the probability of exercise and the operational consequence of losing those sites from the SMO's network. High-volume sites with strong enrollment track records that exercise termination rights create an immediate valuation impairment that should be modeled as a downside case in the acquisition analysis.

Where the SMO holds equity interests in affiliated sites, the consent and succession analysis is more complex. The change of control of the SMO transfers those equity interests to the acquirer, which may affect the sites' governance, their relationships with institutional creditors, and their regulatory designations. Some state medical practice acts restrict ownership of clinical research sites to licensed physicians, and an SMO acquisition that results in a non-physician entity holding equity in a site entity may raise licensure questions in states with corporate practice of medicine laws. Buyers of SMOs must assess the equity structure of every affiliated site entity and confirm that the post-closing ownership structure satisfies applicable state regulatory requirements.

Purchase Agreement Representations: CTA Validity, No Material Breaches, and Consents Obtained

The purchase agreement representations relating to clinical trial agreements are the formal legal embodiment of everything the diligence workstream has identified. They must be drafted with precision, because the scope of any surviving indemnification obligation will be defined by whether the actual facts at closing deviated from what the seller represented. Boilerplate reps that simply state that all CTAs are in full force and effect, without addressing the specific risk categories identified in a CRO transaction, provide inadequate protection.

A well-drafted CTA validity representation confirms that each CTA listed on the disclosure schedule is a valid and binding obligation of the contracting CRO entity, enforceable in accordance with its terms. It further confirms that no counterparty has given written notice of default, no material breach has occurred and is continuing, and no event has occurred that with the passage of time or giving of notice would constitute a material breach. In the CRO context, a material breach could include failure to make timely investigator payments, failure to conduct monitoring visits as required by the protocol, or failure to submit regulatory reports to the sponsor in accordance with the CTA's governance requirements.

The consents obtained representation is the critical pre-closing deliverable in any CRO transaction where the CTA portfolio includes agreements requiring site consent for change of control. The representation should state that all required third-party consents, approvals, and notifications have been obtained or given as required by the terms of the identified CTAs, and that no consent requirement has been waived without the counterparty's agreement. Where some consents are outstanding at closing, the purchase agreement typically addresses these through a carve-out to the representation coupled with a post-closing covenant requiring the parties to cooperate in obtaining the remaining consents, and a holdback or escrow mechanism that provides the buyer with protection if a non-consenting site terminates its CTA after closing.

Special indemnifications for CTA-related liabilities in CRO acquisitions should address three categories that the general indemnification provisions may not adequately cover. First, pre-closing investigator payment arrears that the seller did not disclose and that the buyer discovers through post-closing site audits. Second, pre-closing IRB compliance failures, including failure to notify IRBs of adverse events or protocol deviations as required by the CTAs, that expose the acquired CRO to regulatory sanction after closing. Third, pre-closing indemnification obligations to sites arising from subject adverse events or data integrity disputes that were known or knowable to the seller but not disclosed in the acquisition data room. Each of these categories warrants a specific indemnification carve-out with its own survival period, basket, and cap, calibrated to the materiality of the identified exposure and the ability of the seller to fund the obligation if it is asserted after closing. For counsel advising on CRO transactions, contact Acquisition Stars at 248-266-2790 or consult@acquisitionstars.com to discuss the specific consent, indemnification, and IRB coordination issues in a pending transaction.

Frequently Asked Questions

Related Resources

Clinical trial agreement succession in a CRO acquisition is not a post-closing administrative task. The consent campaigns, IRB notifications, investigator payment audits, and purchase agreement representations that govern CTA continuity must be addressed during the diligence period and resolved before the parties can close with confidence that the acquired trial network will operate without interruption. Transactions that treat these obligations as ministerial details routinely discover that they are, in fact, material liabilities.

The legal framework for CTA succession touches contract law, FDA regulatory requirements, HIPAA privacy obligations, and the Common Rule's informed consent and IRB review requirements simultaneously. Counsel who advises on a CRO acquisition must coordinate analysis across all of these domains and integrate the findings into a purchase agreement that accurately allocates the risks that cannot be eliminated before closing.